In Situ Cross-linking Based Co-Fractionation Mass Spectrometry (XL-CoFrac-MS)

ABSTRACT: We developed an in situ cross-linking coupled reversed-phase liquid chromatography-based co-fractionation mass spectrometry (XL-CoFrac-MS) platform to analyze drug-induced protein complex changes. A software tool, ChromaQuant, was built to automate chromatographic peak quantification. Using RS4;11 leukemia cells treated with the BCL-2 inhibitor ABT-199, we demonstrated the ability of the platform to detect BCL-2-associated protein complexes and characterize signaling pathway alterations. This approach enables efficient protein complex profiling and provides mechanistic insights into drug-induced apoptosis.

ORGANISM(S): Homo Sapiens

SUBMITTER: Mingxia Gao  

PROVIDER: PXD067673 | iProX | Sat Aug 23 00:00:00 GMT+01:00 2025

REPOSITORIES: iProX